All In Biotech

Drug Trial Radar · NCT02310906

Phase I/II Study of SRP-4053 in DMD Patients

A 2-Part, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration, Safety, Tolerability, and Pharmacokinetics Study (Part 1) Followed by an Open-Label Efficacy and Safety Evaluation (Part 2) of SRP-4053 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

Last checked: Nov 20, 2026Latest source record: Oct 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

39

Actual

Start

Jan 13, 2015

Primary completion

Mar 25, 2019

Study completion Mar 25, 2019

Sponsor

Lead sponsor
Sarepta Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Institut de Myologie, France; Consultants for Research in Imaging and Spectroscopy; Great Ormond Street Hospital for Children NHS Foundation Trust; Catholic University of the Sacred Heart; Royal Holloway University; SYSNAV; University College, London; University of Newcastle Upon-Tyne
First posted
Dec 8, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 6 years, up to 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, multiple-dose 2-part study to assess the safety, tolerability, efficacy, and pharmacokinetics of SRP-4053 in Duchenne muscular dystrophy (DMD) patients with deletions amenable to exon 53 skipping.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • PlaceboDrug

    SRP-4053 placebo-matching solution for IV infusion.

  • SRP-4053Drug

    SRP-4053 (golodirsen) solution for IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to DiscontinuationTime frame: Baseline up to Week 12
  2. Part 1: Number of Participants With Potentially Clinically Significant (PCS) Laboratory Abnormalities Reported as TEAEsTime frame: Baseline up to Week 12
  3. Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEsTime frame: Baseline up to Week 12
  4. Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Physical ExaminationsTime frame: Baseline up to Week 12
  5. Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEsTime frame: Baseline up to Week 12
  6. Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO)Time frame: Baseline up to Week 12
  7. Part 2a: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Total Golodirsen GroupTime frame: Baseline and Week 144
  8. Part 2b: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Untreated Group (Non-exon 53 Amenable Participants)Time frame: Baseline and Week 144
  9. Part 2a: Change From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 48 in Total Golodirsen GroupTime frame: Baseline, Week 48

Locations

5 sites in 4 countries. Site status is shown where the registry gives one.

  • Boston Children's Hospital

    Boston, Massachusetts

  • Institute de Myologie

    Paris, France

  • Policlinico Universitario A Gemelli

    Rome, Italy

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London, United Kingdom

  • Newcastle University Hospital

    Newcastle, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.